Pirlimycin is a lincosaminide antibiotic that is active against gram-positive mastitis pathogens such as Streptococcus uberis, Streptococcus dysgalactiae subsp. dysgalactiae and Streptococcus agalactiae. Pirlimycin binds to the 50s ribosomal subunit of mRNA and inhibits protein synthesis. In clinical studies, 50 mg of pirlimycin administered twice at a 24-hour interval (2X) into each affected quarter was shown to be the effective dose for treatment of mastitis caused by gram-positive pathogens in lactating dairy cattle (1). The length of time pirlimycin concentrations in milk remains above the minimum inhibitory concentration of the susceptible bacteria is key to pirlimycin's efficacy. Theoretically, lengthening the duration of pirlimycin therapy should increase efficacy.
展开▼
